+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer



Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Radium-223 is the preferred therapy in bone-predominant symptomatic metastatic castration-resistant prostate cancer



Clinical Advances in Hematology and Oncology 13(5): 293-298




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 057530313

Download citation: RISBibTeXText

PMID: 26352773


Related references

Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer. Clinical Advances in Hematology and Oncology 13(5): 293-295, 2016

F13Era 223-A Phase 3 Trial of Radium-223 Dichloride (Ra-223) in Combination with Abiraterone Acetate (Aa) and prednisone in the treatment of asymptomatic or mildly symptomatic chemotherapynave patients with bone-predominant metastatic Castration Resistant Prostate Cancer (Crpc). Annals of Oncology 26(Suppl 6): vi57.1-vi57, 2015

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. European Urology 2017, 2017

Alpha emitter radium-223 dichloride: new therapy in castration-resistant prostate cancer with symptomatic bone metastases. Der Urologe. Ausg. a 53(4): 519-523, 2014

Mp87-11 Interim Analysis Of An Open Label Phase Ii Study Of Enzalutamide And Radium Ra 233 Dichloride In Symptomatic, Metastatic Castration-Resistant Prostate Cancer Patients. The Journal of Urology 199(4): e1191-e1192, 2018

Bone-specific therapy with radium-223 dichloride : Castration-resistant prostate cancer with symptomatic bone metastases. Der Urologe. Ausg. a 56(1): 24-31, 2017

Comparative Analysis Of Radium-223 Versus Placebo In Symptomatic Metastatic Castration Resistant Prostate Cancer Treated With Best Standard Of Care On Skeletal-Related Events Outcomes. Value in Health 16(3): A133-A134, 2013

Radium-223 dichloride for the treatment of castration-resistant prostate cancer with symptomatic bone metastases. Expert Review of Clinical Pharmacology 10(8): 809-819, 2017

Radium-223 dichloride: a review of its use in patients with castration-resistant prostate cancer with symptomatic bone metastases. Drugs 74(5): 579-586, 2015

Radium-223: Insight and Perspectives in Bone-metastatic Castration-resistant Prostate Cancer. Anticancer Research 36(11): 5719-5730, 2016

Real world lessons for optimal selection of patients with bone metastatic castration-resistant prostate cancer for radium-223 therapy. European Urology Suppl.s 16(10): E2691-E2692, 2017

Patient Selection for Radium-223 Therapy in Patients With Bone Metastatic Castration-Resistant Prostate Cancer: New Recommendations and Future Perspectives. Clinical Genitourinary Cancer 2018, 2018

Radium-223 dichloride: a novel treatment option for castration-resistant prostate cancer patients with symptomatic bone metastases. Annals of PharmacoTherapy 49(4): 469-476, 2015

Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. Lancet. Oncology 15(12): 1397-1406, 2015

EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging 45(5): 824-845, 2017